In Sue's Name, 127 Wynchgate, London (2026)

05/06/2026

𝗛𝗼𝗻𝗼𝘂𝗿𝗶𝗻𝗴 𝗟𝗼𝘃𝗲𝗱 𝗢𝗻𝗲𝘀 & 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝗶𝗴𝗵𝘁 𝗔𝗴𝗮𝗶𝗻𝘀𝘁 𝗕𝗿𝗮𝗶𝗻 𝗧𝘂𝗺𝗼𝘂𝗿𝘀 🎗️

This week on Wednesday, 3rd June, myself, the In Sue’s Name team, alongside our partners at Brain Tumour Research, visited the Blizard Institute at Queen Mary University of London for our 2026 Wall of Hope ceremony.

It is always an incredibly moving and poignant day. Alongside a select group of families, we stood together to place personalised magnetic tiles on the Wall of Hope - a powerful, visible tribute to the loved ones we have lost to brain tumours.

𝗕𝘂𝘁 𝘁𝗵𝗲𝘀𝗲 𝘁𝗶𝗹𝗲𝘀 𝗿𝗲𝗽𝗿𝗲𝘀𝗲𝗻𝘁 𝘀𝗼 𝗺𝘂𝗰𝗵 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝗮 𝗺𝗲𝗺𝗼𝗿𝗶𝗮𝗹:
Sponsoring Vital Science: Every single tile placed represents a £2,740 donation, which completely funds a full day of critical, life-saving research at the institute.

𝗖𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗖𝘂𝗿𝗲: Our families had the opportunity to tour the laboratories, look through the microscopes, and meet the incredible team of scientists, led by Professor Silvia Marino, who are working tirelessly every day to find a cure.

𝗔 𝗟𝗮𝘀𝘁𝗶𝗻𝗴 𝗟𝗲𝗴𝗮𝗰𝘆: While the physical tiles remain next to the labs for 5 years to inspire the scientists doing the work, the stories and memories of those we honour are preserved permanently in a digital memory book.
We do this because the statistics around brain tumours remain unacceptable, and sustainable, dedicated research is the only way forward.

𝗛𝗼𝘄 𝗬𝗼𝘂 𝗖𝗮𝗻 𝗚𝗲𝘁 𝗜𝗻𝘃𝗼𝗹𝘃𝗲𝗱
If you would like to honour a loved one, celebrate a legacy, and directly sponsor a day of research that brings us closer to a cure, In Sue’s Name is here to support you through the process.

📩 DM us directly or get in touch with me to find out how you can place a tile on the Wall of Hope.

𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿, 𝘄𝗲 𝗮𝗿𝗲 𝘁𝘂𝗿𝗻𝗶𝗻𝗴 𝗴𝗿𝗶𝗲𝗳 𝗶𝗻𝘁𝗼 𝗮𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝗶𝗴𝗵𝘁.

Brain Tumour Research In Sue's Name

28/05/2026

"If you have good thoughts they will shine out of your face like sunbeams and you will always look lovely Dahl . This wonderful quote sums up our beautiful daughter Sue. She was always smiling and full of love, it radiated from her soul. her compassion was always there for those who needed it . We all miss that wonderful smile every day of our lives.
www.insuesname.org.uk

20/05/2026

What makes me get up every morning and look forward to networking and meeting new people, learning about them and growing my circle of knowledge. 15 years ago we lost our beautiful eldest daughter Sue after a short 6 week illness from Brain Tumours. Having spent 3 years feeling sorry for myself, I decided I wanted to keep my daughter's name alive and raise money for Brain Tumour Research in her name.

Sue was bubbly personality who loved helping people and adored her 2 children Sasha and Daniel and took part in 5 Race for Life Runs and a Sky dive for Cancer Research.

As our first born she and I were very close and before she got married she had a studio photo done and said "Dad I know I am moving out, but hang this picture in your office and I will be always with you. That is the first thing I do each morning and it fires me up for the day even at the age of 84 and her presence has helped us raise £650k!

I believe that love transcends death and whenever I am low or need help with an event, Sue seems to reach out and help solve that problem.

God Bless you darling Sue, keep your angel prayers for your children and your lovely granddaughter Aleeyah Sue. www.insuesname.org.uk

14/05/2026

𝗧𝗲𝗲 𝗼𝗳𝗳 𝗳𝗼𝗿 𝗮 𝗰𝗮𝘂𝘀𝗲 𝘁𝗵𝗮𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀. ⛳️

𝗖𝗮𝗹𝗹𝗶𝗻𝗴 𝗮𝗹𝗹 𝗡𝗼𝗿𝘁𝗵 𝗟𝗼𝗻𝗱𝗼𝗻 𝗮𝗻𝗱 𝗛𝗲𝗿𝘁𝘀 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗹𝗲𝗮𝗱𝗲𝗿𝘀 𝗮𝗻𝗱 𝗴𝗼𝗹𝗳𝗲𝗿𝘀! 𝗔𝗿𝗲 𝘆𝗼𝘂 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿 𝗮 𝘄𝗮𝘆 𝘁𝗼 𝘁𝗿𝗲𝗮𝘁 𝘆𝗼𝘂𝗿 𝘁𝗲𝗮𝗺 𝗼𝗿 𝗰𝗹𝗶𝗲𝗻𝘁𝘀 𝘄𝗵𝗶𝗹𝗲 𝗺𝗮𝗸𝗶𝗻𝗴 𝗮 𝗴𝗲𝗻𝘂𝗶𝗻𝗲 𝗶𝗺𝗽𝗮𝗰𝘁?

Join us for the In Sue’s Name 2026 Golf Day at the prestigious South Herts Golf Club. We’re bringing together local businesses for a day of networking, sport, and fundraising in our mission to fund vital brain tumour research.

𝗧𝗵𝗲 𝗜𝘁𝗶𝗻𝗲𝗿𝗮𝗿𝘆:
🥓 Morning: Kick off with coffee and classic bacon sandwiches.
⛳️ Midday: 18 holes on one of the most beautiful courses in the county.
🍽 Evening: A sit-down meal to celebrate the day’s winners and share our mission.

Brain tumours are the biggest cancer killer of children and adults under 40, yet research remains critically underfunded.Every swing you take helps us get closer to a cure.

Interested in entering a team or sponsorship opportunities?
👇 Drop a comment below or DM David Alan Taylor for the registration details!

10/05/2026

Did you know this statistic ?

Less than 1% of Cancer Research Funding goes into fighting this terrible disease !

Our beautiful daughter Sue died at 42 ! Want to know more see

www.insuesname.org.uk

29/04/2026

𝗠𝘆 𝘆𝗲𝗮𝗿 𝗼𝗳 𝗿𝗮𝗶𝘀𝗶𝗻𝗴 𝗮𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀

Amazing work by Rebecca!

Rebecca John, 38, from Gloucester, is taking on an incredible challenge of completing a half marathon every month in 2026, in honour of her brother and close friend who have both been diagnosed with brain tumours. She shares what motivates her to keep running and why she’s determined to raise awareness of this devastating disease.

𝐼’𝑣𝑒 𝑎𝑙𝑤𝑎𝑦𝑠 ℎ𝑎𝑑 𝑎 𝑐𝑙𝑜𝑠𝑒 𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛𝑠ℎ𝑖𝑝 𝑤𝑖𝑡ℎ 𝑚𝑦 𝑏𝑟𝑜𝑡ℎ𝑒𝑟 𝑅𝑖𝑐ℎ, 𝑠𝑝𝑒𝑛𝑑𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 𝑎𝑡 𝑒𝑎𝑐ℎ 𝑜𝑡ℎ𝑒𝑟’𝑠 ℎ𝑜𝑢𝑠𝑒𝑠, 𝑔𝑜𝑖𝑛𝑔 𝑡𝑜 𝑡ℎ𝑒 𝑡ℎ𝑒𝑎𝑡𝑟𝑒 𝑡𝑜𝑔𝑒𝑡ℎ𝑒𝑟, 𝑤𝑎𝑙𝑘𝑖𝑛𝑔, 𝑛𝑖𝑔ℎ𝑡𝑠 𝑜𝑢𝑡 𝑎𝑛𝑑 𝑒𝑛𝑗𝑜𝑦𝑖𝑛𝑔 𝑏𝑒𝑖𝑛𝑔 𝑤𝑖𝑡ℎ 𝑜𝑢𝑟 𝑓𝑎𝑚𝑖𝑙𝑦.

𝐼 ℎ𝑎𝑑 𝑛𝑜 𝑤𝑜𝑟𝑑𝑠 𝑤ℎ𝑒𝑛 ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑡𝑜𝑙𝑑 𝑚𝑒 𝑎𝑏𝑜𝑢𝑡 ℎ𝑖𝑠 𝑏𝑟𝑎𝑖𝑛 𝑡𝑢𝑚𝑜𝑢𝑟 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑖𝑛 2023, 𝐼 𝑤𝑎𝑠 𝑗𝑢𝑠𝑡 𝑠𝑜 𝑠ℎ𝑜𝑐𝑘𝑒𝑑. 𝑇ℎ𝑒𝑛 𝐼 𝑏𝑒𝑐𝑎𝑚𝑒 𝑢𝑝𝑠𝑒𝑡 𝑎𝑛𝑑 𝑤𝑜𝑟𝑟𝑖𝑒𝑑 𝑎𝑏𝑜𝑢𝑡 ℎ𝑜𝑤 ℎ𝑒 𝑤𝑎𝑠 𝑓𝑒𝑒𝑙𝑖𝑛𝑔, ℎ𝑜𝑤 ℎ𝑒’𝑑 𝑔𝑒𝑡 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝑡ℎ𝑖𝑠 𝑎𝑛𝑑 ℎ𝑜𝑤 ℎ𝑖𝑠 𝑐ℎ𝑖𝑙𝑑𝑟𝑒𝑛 𝑎𝑛𝑑 𝑤𝑖𝑓𝑒 𝑤𝑜𝑢𝑙𝑑 𝑐𝑜𝑝𝑒. 𝐼 𝑘𝑒𝑝𝑡 𝑡ℎ𝑖𝑛𝑘𝑖𝑛𝑔 𝑎𝑏𝑜𝑢𝑡 𝑡ℎ𝑒 𝑓𝑢𝑡𝑢𝑟𝑒 𝑎𝑛𝑑 𝑤ℎ𝑎𝑡 𝑤𝑜𝑢𝑙𝑑 ℎ𝑎𝑝𝑝𝑒𝑛 𝑡𝑜 ℎ𝑖𝑚. 𝐼𝑚𝑚𝑒𝑑𝑖𝑎𝑡𝑒𝑙𝑦 𝑎𝑓𝑡𝑒𝑟 𝑏𝑒𝑖𝑛𝑔 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑒𝑑 𝑤𝑖𝑡ℎ 𝑎 𝑚𝑒𝑛𝑖𝑛𝑔𝑖𝑜𝑚𝑎, 𝑅𝑖𝑐ℎ 𝑢𝑛𝑑𝑒𝑟𝑤𝑒𝑛𝑡 𝑠𝑢𝑟𝑔𝑒𝑟𝑦 𝑡𝑜 ℎ𝑎𝑣𝑒 𝑡ℎ𝑒 𝑡𝑢𝑚𝑜𝑢𝑟 𝑟𝑒𝑚𝑜𝑣𝑒𝑑. 𝐻𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑞𝑢𝑖𝑡𝑒 𝑤𝑒𝑙𝑙 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑚𝑎𝑗𝑜𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑎𝑛𝑑 𝑖𝑠 𝑠𝑙𝑜𝑤𝑙𝑦 𝑔𝑒𝑡𝑡𝑖𝑛𝑔 ℎ𝑖𝑠 𝑓𝑖𝑡𝑛𝑒𝑠𝑠 𝑏𝑎𝑐𝑘. 𝐵𝑢𝑡 𝑖𝑡 𝑤𝑎𝑠 𝑎𝑛 𝑒𝑥𝑡𝑟𝑒𝑚𝑒𝑙𝑦 𝑠𝑡𝑟𝑒𝑠𝑠𝑓𝑢𝑙 𝑎𝑛𝑑 𝑤𝑜𝑟𝑟𝑦𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑤ℎ𝑜𝑙𝑒 𝑓𝑎𝑚𝑖𝑙𝑦.

𝐽𝑢𝑠𝑡 𝑡𝑤𝑜 𝑦𝑒𝑎𝑟𝑠 𝑙𝑎𝑡𝑒𝑟, 𝐼 𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑑 𝑡ℎ𝑒 𝑡𝑒𝑟𝑟𝑖𝑏𝑙𝑒 𝑛𝑒𝑤𝑠 𝑡ℎ𝑎𝑡 𝑚𝑦 𝑔𝑜𝑜𝑑 𝑓𝑟𝑖𝑒𝑛𝑑 𝐿𝑎𝑢𝑟a…

Read the full article here on the website:
https://braintumourresearch.org/blogs/latest-news/my-year-of-raising-awareness-by-running-a-half-marathon-every-month

09/04/2026

More positive news - Promising results for potential new glioblastoma treatment

A promising new treatment for glioblastoma has been shown to eliminate the tumour and prevent recurrence in animal studies, achieving what researchers “thought impossible”.

Trogenix has announced the publication of its breakthrough pre-clinical data in Nature, reporting complete tumour eradication in 83% of treated cases and durable protection in a brain cancer model that closely mimics human glioblastoma.

The publication, authored by scientists from the University of Edinburgh, UCL Cancer Institute and The Royal Infirmary of Edinburgh, focuses on Trogenix’s unique Synthetic Super-Enhancers (SSEs) technology. Trogenix, co-founded by Professor Steve Pollard, is a spin out from the University of Edinburgh and this work was funded by Cancer Research UK and the Biotechnology and Biological Sciences Research Council.

The gene therapy uses a harmless viral vector (a specially engineered virus which acts as a vehicle) to deliver genetic instructions specifically to glioblastoma tumours. Once inside the tumour cells, these genetic instructions prompt the cell to produce a toxic substance, and also trigger the immune system to attack glioblastoma cells. You can read more about this approach in our blog.

In the study, single dose of SSEs caused tumours to shrink within one to two weeks. In 83% of the treated cases, the tumour disappeared entirely over the subsequent two to three weeks. The research team also gathered evidence of precision immune activation, meaning it triggered the immune system to specifically eliminate the tumour while SSE activity remained undetected in healthy normal brain cells. Excitingly, over the following 11 months, tumours did not return after the initial treatment and there were no harmful side effects...

Read the full article on the Brain Tumour Research website using the link in the comments section.

07/04/2026

First new adult brain tumour treatment in 20 years approved
This is fantastic news!
A new drug to treat low-grade glioma has been approved for use on the NHS in England and Wales.
The National Institute for Health and Care Excellence (NICE) has today approved vorasidenib to treat adults and children aged 12 years and older, with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase mutation (IDH1 or IDH2).
The drug will be offered to patients who have undergone surgery, but who are not in need of immediate radiotherapy and chemotherapy. It is the first targeted systemic therapy approved for IDH-mutant low-grade glioma.
Read more about how vorasidenib works on our blog.
Based on NICE’s draft guidance, published today, immediate access is available to eligible patients via interim funding through the Cancer Drugs Fund (CDF). For more information, read the full guidance on NICE’s website.
Earlier this month, the Scottish Medicines Consortium approved vorasidenib for suitable patients through NHS Scotland...
Read the full article on the Brain Tumour Research website using the link in the comments section.

In Sue's Name

05/06/2026

28/05/2026

20/05/2026

14/05/2026

10/05/2026

29/04/2026

09/04/2026

07/04/2026

Address

Telephone

Website

Alerts

Contact The Organisation

Shortcuts

Featured

Share

Category